drugset / Trial / NCT02422498
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Phase 2
Active not recruiting
49 enrolled
Memorial Sloan Kettering Cancer Center
Cedars-Sinai Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is being done to find out if the results of a pre-treatment biopsy can predict response to cisplatin and radiation treatment for patients with metastatic or recurrent triple negative breast cancer.
Timeline
- Start
- 2015-04-14
- Primary completion
- 2022-12-19
- Completion
- 2028-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |